21+ verification
All products are sold strictly for laboratory research use only and are not for human or animal consumption. You must be 21 or older to enter.
By entering you accept the research-use-only terms and confirm you are a qualified buyer.
USP <71> is the compendial sterility test governing pharmaceutical and biological products, and it requires a 14 day incubation in two separate media before a sample can be called sterile. Most research peptide vials, including lyophilized powders with a clean HPLC purity certificate, are not sterile by default unless a lab has run this exact test on that batch. The practical rule for anyone handling peptides: check the certificate of analysis for a documented sterility result before assuming a vial is safe to use, and follow aseptic technique regardless of what the paperwork says.
TL;DR:
- Most peptide vials are not sterile by default; a documented sterility test must confirm their safety beyond HPLC purity certification.
- Filtration is generally preferred over direct inoculation for sensitivity, but it requires thorough rinsing to prevent false negatives caused by preservatives.
- Running the correct media, incubation, and sampling standards is crucial, and a product passing USP <71> does not guarantee absence of endotoxin.
- Method suitability testing with challenge organisms and validation are essential, especially when formulation changes occur or certification lacks validation data.
- Rapid microbe detection methods can screen early but cannot replace the full 14-day USP <71> test for final batch release.
USP <71> recognizes two ways to run a sterility test, and the choice between them depends heavily on what’s actually in the sample. Membrane filtration and direct inoculation are the two compendial methods, and for peptide research, filtration is the default unless the formulation makes it impossible.
Membrane filtration works by passing the entire sample volume through a filter that traps any microorganisms present, then incubating that filter in growth media. The standard pore size is 0.45 µm, small enough to catch bacteria and fungi but large enough to let a filterable liquid pass through at a reasonable rate. Here’s the actual workflow a lab technician follows:
Filtration earns its place as the preferred method because it concentrates organisms from a larger sample volume onto a single trapping surface, which increases the odds of catching a low-level contaminant that direct inoculation might miss. The rinsing step matters as much as the filtration itself. Skip an adequate rinse and a peptide sample containing a bacteriostatic preservative can suppress any organisms trapped on the membrane, producing a clean result that reflects the antimicrobial, not the sample.
Direct inoculation skips filtration entirely. A measured volume of the sample goes straight into each growth medium. It’s simpler to execute and requires no filtration apparatus, but it comes with a real tradeoff: any inhibitory substance in the peptide solution, whether a preservative, a high peptide concentration, or a solvent, stays in the media at full strength and can mask contamination. Direct inoculation tends to get reserved for samples that can’t be filtered, viscous formulations, oil-based suspensions, or products where filtration would strip out the very organisms you’re trying to detect.
For a typical reconstituted research peptide solution, filtration usually wins on sensitivity. For a thick or emulsified formulation that clogs filters or resists membrane passage, direct inoculation becomes the only workable option, even though it sacrifices some detection power. A lab running sterility testing peptides work at any volume should default to filtration and only fall back to direct inoculation when the sample’s physical properties force the issue.
Running the test correctly means matching several fixed parameters that the compendium spells out in detail, and getting any one of them wrong invalidates the result.
That last point deserves emphasis because it’s where most misreadings happen. USP <71> is a qualitative, pass or fail test performed on a statistical sample of a batch, not an exhaustive screen of every unit. It also tells you nothing about endotoxin. A vial can pass sterility testing cleanly and still carry pyrogenic bacterial residue from dead organisms, which is a separate concern covered under a different test entirely. Regulatory bodies frame sterility testing as one piece of a broader quality picture, and FDA guidance treats it alongside environmental monitoring, aseptic process validation, and container closure integrity rather than as a standalone guarantee.
A sterility test only means something if the lab has already proven the method can detect a live organism in that specific peptide matrix. This step, called method suitability, has to happen before or alongside the actual sterility test on a new product, and it’s the part most non-accredited operations skip or shortcut.
Pro Tip: If a vendor’s certificate of analysis lists a sterility result but no corresponding method suitability data, ask for it directly. A sterility pass without proof the method could actually detect contamination in that matrix is not a meaningful result.
Growth in a sterility test triggers a specific diagnostic sequence, not an automatic batch rejection, because contamination introduced during testing itself is common enough that labs have to rule it out first.
Isolators reduce false positives more reliably than open biosafety cabinets or laminar flow hoods because they physically separate the sample from the operator and room air throughout the entire procedure. Industry technical guidance consistently points to isolators as the preferred containment for sterility testing precisely because they cut down the operator- and environment-driven contamination that produces spurious positives in open systems. False negatives run the other direction: a highly antimicrobial peptide formulation, an inadequate rinse step, or too small a sample volume can all let real contamination slip past undetected. Adequate rinsing and correct sample volumes aren’t procedural formalities. They’re the difference between a result you can trust and one that only looks clean.
A purity number on a certificate of analysis tells you almost nothing about whether a peptide is sterile. HPLC purity measures chemical composition, not microbial contamination, and lyophilized peptide powders are typically non-sterile unless a batch-matched sterility test says otherwise. Treat that distinction as a starting assumption, not an edge case.
Reconstitution is where most microbial risk gets introduced or controlled, depending on how it’s done. A defensible workflow looks like this:
That 0.22 µm filtration step deserves a caveat researchers often miss. Filtering through a 0.22 µm membrane removes viable bacteria and fungi from the solution, but it does not remove endotoxin, since endotoxin molecules are far smaller than the filter’s pore size and pass straight through. Filtration and bacteriostatic water are harm-reduction tools, useful and genuinely protective, but they are not a substitute for a documented USP <71> result on the batch. One reduces the chance of introducing new contamination during handling; the other proves the original material was clean.
Pro Tip: Build a five-point pre-use checklist and run it on every vial: confirm the COA lists a sterility method by name, check the test date against the manufacture date, confirm the testing lab’s accreditation, follow a written reconstitution SOP rather than an improvised process, and store the reconstituted solution exactly as directed.
ATP bioluminescence, PCR, and flow cytometry all give researchers a faster read on microbial presence than the 14 day compendial test, and each has a legitimate place in a peptide lab’s workflow, just not as a release decision on their own.
A sound workflow runs rapid screening on incoming materials or in-process samples to catch gross contamination early, then confirms release-quality batches with the full 14 day USP <71> test regardless of how clean the rapid screen looked.
A COA that actually supports a sterility claim names the test method, states the testing lab and its accreditation, and lists the batch ID alongside a test date reasonably close to the manufacture date, generally within about 30 days. It should also include growth promotion or method suitability data proving the test could detect contamination in that specific matrix. ISO/IEC 17025 accreditation is the marker to look for when confirming the testing lab itself meets recognized competency standards, rather than being an in-house or unaccredited operation.
Sterility and endotoxin are two different tests measuring two different risks, and a sterility pass never implies a pyrogen-free result. Watch for these red flags on any vendor documentation:
The gap in most sterility testing advice isn’t the science, it’s the assumption that a peptide vial’s job is done once purity is confirmed. Purity and sterility measure completely different things, and treating a high HPLC number as a proxy for microbial safety is the single most common mistake researchers make when handling reconstituted peptides.
Conventional advice tends to stop at “filter your solution and you’re fine.” That’s incomplete. Filtration through a 0.22 µm membrane is real risk reduction, but it can’t retroactively sterilize a vial that was never tested, and it does nothing for endotoxin. The researchers who get this right treat COA verification as a first-class step, not paperwork to skim past, and they build reconstitution habits that assume contamination risk exists until proven otherwise.
If there’s one priority to take from this, it’s sequencing: verify the sterility documentation before you reconstitute, not after you notice something looks off in culture. Everything downstream, filtration, storage, handling, is damage control if that first check gets skipped.
— Mitch
